Somapacitan, a once‐weekly reversible albumin‐binding <scp>GH</scp> derivative, in children with <scp>GH</scp> deficiency: A randomized dose‐escalation trial

Abstract

Single doses of once-weekly somapacitan (0.02-0.16 mg/kg) were well tolerated in children with GHD, with IGF-I profiles supporting a once-weekly treatment profile. No clinically significant safety/tolerability signals or immunogenicity concerns were identified.